Seville, Spain, Sunday 18 April 2004. New data show CRESTORTM (rosuvastatin) provides superior reductions in a major cardiovascular risk factor, LDL-cholesterol (LDL-C), in patients with type 2 diabetes and dyslipidaemia compared to atorvastatin.1-3 Results from the CORALL study demonstrated that for each dose of CRESTOR, LDL-C was reduced significantly more than with double the dose of atorvastatin; LDL-C was reduced by 46%, 51% and 54% with CRESTOR 10mg, 20mg and 40mg respectively compared to 41%, 46% and 48% with atorvastatin 20mg, 40mg and 80mg, respectively (all p<0.05).1 CORALL is one of three new studies with CRESTOR presented at the European Atherosclerosis Society (EAS) Congress in this patient population.1-3

People with type 2 diabetes are three times more likely to die from a cardiovascular event than non-diabetics with the same cholesterol level and up to 80% die of cardiovascular disease.4 Reducing high levels of LDL-C is recognised as one of the primary treatment targets for type 2 diabetics5, 6 and lowering LDL-C with statin treatment has been demonstrated to be effective in reducing cardiovascular events in these patients.7-10 The latest US and European guidelines now set the low and challenging LDL-C goal of <2.5 mmol/L (100mg/dL) for these high risk patients.5, 6 A growing body of evidence suggests that additional prevention of major cardiovascular events may be achieved through lowering LDL-C levels below what was previously accepted as sufficient. A recent study has confirmed that a statin providing more effective reductions in LDL-C (by 42%) leads to greater protection against death or major cardiovascular events than standard statin treatment.11

Results presented today from the ANDROMEDA study show that low doses of CRESTOR reduced LDL-C by at least 50% and got more than 90% of patients with type 2 diabetes and dyslipidaemia to their new European LDL-C goal of <2.5 mmol/L.2 Also in this study, CRESTOR 10mg and 20mg
'"/>

Contact: Francesca Zino
francesca.zino@shirehealthinternational.com
Shire Health International
19-Apr-2004

Page: 1 2 3 4
Related medicine news :

1. CRESTOR leads in 1st international prospective study of statins in the metabolic syndrome
2. CRESTOR (TM) improves apolipoprotein and lipid ratios - markers of cardiovascular disease risk
3. New highly active agents against sandfly fever
4. Engineers develop biowarfare sensing elements for future highly sensitive nerve-gas detectors
5. Patients with cancer have highly increased risk for blood clots
6. Inflammatory cells highly promising target in NF 1
7. Multi-center study finds therapy boosts kidney transplants in highly sensitized patients
8. Columbia Univ. Medical Center wins highly competitive stroke grant from NIH
9. Study showed vitamin D inadequacy highly prevalent among women treated for osteoporosis
10. World mental health surveys find mental disorders highly prevalent and often untreated
11. MRI highly useful in the evaluation of patients with uterine fibroids